What is the initial referral in RP management to determine gene therapy candidacy?

What is the initial referral in RP management to determine gene therapy candidacy?

• A. Genetic testing to assess candidacy for gene therapy
• B. Laser photocoagulation
• C. Corneal transplant
• D. Vision therapy

Answer: (A)

In RP management, identifying the exact genetic mutation is the key step to determine gene therapy candidacy. Gene therapies are designed to target specific genetic defects, so knowing which mutation is causing the disease tells you whether a patient may be eligible for current or future treatments. Genetic testing confirms the diagnosis, clarifies the precise mutation, and guides enrollment in appropriate trials or approved therapies (for example, therapies exist for certain mutations like RPE65). After a pathogenic variant is identified, additional assessments of vision and retinal structure can help gauge overall suitability, but the mutation itself is what gates gene therapy eligibility. The other options don’t establish this eligibility: laser photocoagulation addresses retinal conditions or complications rather than genetic targets; a corneal transplant treats corneal disease; and vision therapy does not determine gene-targeted treatment eligibility.

In RP management, identifying the exact genetic mutation is the key step to determine gene therapy candidacy. Gene therapies are designed to target specific genetic defects, so knowing which mutation is causing the disease tells you whether a patient may be eligible for current or future treatments. Genetic testing confirms the diagnosis, clarifies the precise mutation, and guides enrollment in appropriate trials or approved therapies (for example, therapies exist for certain mutations like RPE65). After a pathogenic variant is identified, additional assessments of vision and retinal structure can help gauge overall suitability, but the mutation itself is what gates gene therapy eligibility. The other options don’t establish this eligibility: laser photocoagulation addresses retinal conditions or complications rather than genetic targets; a corneal transplant treats corneal disease; and vision therapy does not determine gene-targeted treatment eligibility.